Loading organizations...
Seido Capital is a venture capital firm founded in 2003 and based in Montreal, Canada. The firm specializes in early and growth-stage investments within the life sciences and deep tech sectors, including healthcare, across North America. It aims to support companies from their pre-seed phase through to IPO, identifying ventures with significant potential for market impact.
With $150 million in assets under management and a track record spanning 20 years, Seido Capital offers more than just funding. It provides strategic advice and operational expertise to help innovators develop their ideas into successful market solutions, guiding them through various growth milestones.
Key people at Seido Capital.
Seido Capital focuses on life sciences and deep tech, including healthcare, investing in companies from pre-seed to IPO stages, with an emphasis on early and growth-stage ventures.
Beyond capital, Seido Capital offers strategic guidance and expertise to help innovators develop their ideas and navigate market challenges.
Seido Capital focuses on life sciences and deep tech, including healthcare, investing in companies from pre-seed to IPO stages, with an emphasis on early and growth-stage ventures.
Beyond capital, Seido Capital offers strategic guidance and expertise to help innovators develop their ideas and navigate market challenges.
Seido Capital is a venture capital investment firm established in 2003, with its headquarters located in Montreal, Canada. The firm operates with a focus on identifying and supporting innovative companies within the North American venture ecosystem. It is structured to provide capital and strategic support to emerging businesses.
The firm's investment strategy primarily targets companies in the life sciences and deep tech sectors. This includes a strong emphasis on early and growth-stage healthcare ventures. Seido Capital has the capacity to invest across a broad spectrum of company development, from pre-seed rounds through to initial public offerings.
Beyond financial investment, Seido Capital actively engages with its portfolio companies by offering strategic guidance and leveraging its expertise. This approach is designed to assist founders in navigating market challenges and accelerating their growth, helping to translate scientific and technological advancements into viable commercial products.
Seido Capital manages $150 million in assets. The firm draws on over two decades of experience, having built a track record in venture capital since its inception. This long-standing presence in the market informs its investment decisions and its ability to support its portfolio.
The firm's commitment extends to fostering innovation within its target sectors. By backing companies that are developing transformative technologies and solutions, Seido Capital aims to contribute to advancements in areas critical to health and technology.
Key people at Seido Capital.
Seido Capital has 2 tracked investments across 1 company. The latest tracked deal is $2.4B Series B in Kainova Therapeutics in February 2026.
| Date | Company | Round | Lead Investor(s) | Co-Investor(s) |
|---|---|---|---|---|
| Feb 10, 2026 | Kainova Therapeutics | $2.4B Series B | Investissement Québec | 3B Future Health Fund, Admare Bioinnovations, CTI Life Sciences Fund, Panacea Venture, Schroders Capital, Seventure Partners, Turenne Capital, Viva BioInnovator |
| Feb 9, 2026 | Kainova Therapeutics | $23.5M Series B | Investissement Québec | 3B Future Health Fund, AdMare BIO Innovations, CTI Life Sciences Fund, Panacea Venture, Schroders Capital, Seventure Partners, Turenne Capital, Viva BioInnovator |
